This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Zacks.com featured highlights include Crocs, LATAM Airlines, Arrow Electronics and Phibro Animal Health
by Zacks Equity Research
Crocs, LATAM Airlines, Arrow Electronics and Phibro screen cheap on PEG ratios, pairing solid growth outlooks with value appeal in volatile markets.
ARWNegative Net Change CROXNegative Net Change LTMNegative Net Change PAHCNegative Net Change
computers consumer-discretionary medical transportation
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock?
by Sundeep Ganoria
JAZZ CBD drug Epidiolex tops $1B in annual sales, boosting revenue visibility and cannabis exposure. Is the biotech's growth story just beginning?
JAZZPositive Net Change TLRYNegative Net Change ACBNegative Net Change
biotechs marijuana medical pot-stocks
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
PCRXNegative Net Change USNANegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
XRAY Stock Gains Despite Q4 Earnings Miss on Restructuring Initiative
by Zacks Equity Research
XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.
ANGONegative Net Change ISRGNegative Net Change XRAYNegative Net Change ALCNegative Net Change
earnings medical medical-devices
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
NBIXPositive Net Change USNANegative Net Change XENENegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
by Zacks Equity Research
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
SNYNegative Net Change GILDPositive Net Change CSTLNegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
by Zacks Equity Research
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
SNYNegative Net Change BIIBNegative Net Change DNLINegative Net Change TAKNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Implied Volatility Surging for Rigel Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to RIGL stock based on the movements in the options market lately.
RIGLNegative Net Change
medical
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
SNYNegative Net Change PFENegative Net Change NVAXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
TFX Q4 Earnings & Revenues Miss, Margins Down, Stock Up in After-Market
by Zacks Equity Research
Teleflex Q4 earnings and revenues miss estimates as margins shrink, but shares rise 1.7% after hours amid 2026 growth guidance and portfolio reshuffle.
ISRGNegative Net Change ALGNNegative Net Change CAHPositive Net Change TFXPositive Net Change
earnings medical